McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., . . . Hauschild, A. (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol.
Citação norma ChicagoMcArthur, Grant A., et al. "Safety and Efficacy of Vemurafenib in BRAF(V600E) and BRAF(V600K) Mutation-positive Melanoma (BRIM-3): Extended Follow-up of a Phase 3, Randomised, Open-label Study." Lancet Oncol 2014.
MLA CitationMcArthur, Grant A., et al. "Safety and Efficacy of Vemurafenib in BRAF(V600E) and BRAF(V600K) Mutation-positive Melanoma (BRIM-3): Extended Follow-up of a Phase 3, Randomised, Open-label Study." Lancet Oncol 2014.